http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102365209-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 |
| filingDate | 2018-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102365209-B1 |
| titleOfInvention | Salt of cetagliptin and method for preparing the same, pharmaceutical composition and use |
| abstract | The present invention provides salts of compounds of formula (I), (I) The salt is a crystalline or amorphous phosphate, or a crystalline or amorphous oxalate. In particular, phosphate crystalline form B of the present invention has high crystallinity, low hygroscopicity, and excellent stability, and phosphate crystalline form B has excellent oral bioavailability, excellent durability when administered for a long period of time, and does not easily induce hypoglycemia, and at the same time exhibits a serum DPPIV inhibitory action. great. |
| priorityDate | 2018-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.